Datasheet | October 7, 2025

Delivering Global Antibody-Drug Conjugate (ADC) Development Solutions

iStock-1180568371-antibody-3D

Early discovery and development of antibody-drug conjugates (ADCs) hinges on addressing a series of critical questions that ultimately determine therapeutic success. From the outset, identifying a target antigen with high tumor specificity is essential to maximize selectivity and minimize off-target effects. Equally important is choosing an antibody with optimal binding affinity, structural stability, and manufacturability, as well as designing a payload-linker system that delivers potent cytotoxic activity with precise control and minimal systemic toxicity.

Beyond molecular design, comprehensive in vivo evaluation — including efficacy, pharmacokinetics, and biodistribution — is vital to confirm performance and guide optimization. Each of these steps requires not only technical precision but also deep interdisciplinary expertise and robust infrastructure.

With Labcorp, you gain access to industry-leading scientific capabilities, integrated platforms, and specialized expertise that help streamline ADC discovery and development, thus accelerating your path from concept to clinical application with confidence.

access the Datasheet!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Labcorp Drug Discovery Solutions